Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma

Keyphrases

• Neuroblastoma 100%
• Synergize 100%
• Anti-GD2 100%
• Vorinostat 100%
• Neuroblastoma Cells 40%
• Histone Deacetylase Inhibitor (HDACi) 40%
• High-risk Neuroblastoma 40%
• Tumor 20%
• Tumor Growth 20%
• Sympathetic Nervous System 20%
• In Cancer 20%
• Clinical Efficacy 20%
• Neuroblastoma Tumor 20%
• Combination Therapy 20%
• Targeted Therapy 20%
• Cell Death 20%
• Mechanistic Studies 20%
• Childhood Malignancy 20%
• Cell Surface 20%
• Tumor Microenvironment 20%
• Cancer Treatment 20%
• Tumor Antigen 20%
• Macrophages 20%
• Anti-GD2 Antibody 20%
• Fc Receptor 20%
• Mortality Rate 20%
• Combined Modality Therapy 20%
• Effector Cells 20%
• Systemic Cytokine 20%
• Transplantable 20%
• Myeloid-derived Suppressor Cells 20%
• Epigenetic Modulators 20%
• Clinical Testing 20%
• Multiple Mechanisms 20%
• Cytokine Immunotherapy 20%
• Strong Base 20%

Immunology and Microbiology

• Neuroblastoma Cell 100%
• Immunotherapy 50%
• Cell Death 50%
• Cell Surface 50%
• Tumor Antigen 50%
• Macrophage 50%
• Upregulation 50%
• Mortality Rate 50%
• Effector Cell 50%
• Monoclonal Antibody 50%
• Fc Receptor 50%
• Myeloid-Derived Suppressor Cell 50%
• Cytokine Immunotherapy 50%
• Neurological System 50%

Medicine and Dentistry

• Ganglioneuroblastoma 100%
• Vorinostat 100%
• Neuroblastoma Cell 28%
• Histone Deacetylase Inhibitor 28%
• Neoplasm 14%
• Childhood Cancer 14%
• Tumor Progression 14%
• Sympathetic Nervous System 14%
• Cancer Therapy 14%
• Immunotherapy 14%
• Combination Therapy 14%
• Targeted Therapy 14%
• Cell Death 14%
• Upregulation 14%
• Tumor Microenvironment 14%
• Tumor Antigen 14%
• Macrophage 14%
• Monoclonal Antibody 14%
• Mortality Rate 14%
• Cell Surface 14%
• Effector Cell 14%
• Myeloid-Derived Suppressor Cell 14%
• Fc Receptor 14%
• Cytokine Immunotherapy 14%